(Reuters) - Cipla Ltd, India's second-biggest drugmaker by market capitalization, posted a fourth-quarter profit on Tuesday, but missed analysts' estimates.
Net profit came in at 1.79 billion rupees ($26.30 million) for the quarter ended March 31, compared with a loss of 617.9 million rupees in the year-ago quarter, the company said https://www.bseindia.com/xml-data/corpfiling/AttachLive/2d0d0d7f-af2e-4011-839a-9d5e84a05a76.pdf.
Analysts, on average, had expected a profit of 3.57 billion rupees, according to Thomson Reuters data.
($1 = 68.0650 Indian rupees)
Also Read
(Reporting By Arnab Paul in Bengaluru; Editing by Vyas Mohan)
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app